期刊
CUREUS JOURNAL OF MEDICAL SCIENCE
卷 14, 期 4, 页码 -出版社
CUREUS INC
DOI: 10.7759/cureus.23888
关键词
hematologic neoplasm; new therapies; non-cutaneous bpdcn; venetoclax; blastic plasmacytoid dendritic cell neoplasm
Blastic plasmacytoid dendritic cell neoplasm is a rare hematologic neoplasm with cutaneous, hematologic, and central nervous system involvement. Diagnosis is challenging, and the first-line therapy includes acute lymphoid leukemia-type schemes and allogeneic transplant. New therapies targeting CD 123 and Bcl-2 have shown promise in improving patient survival.
Blastic plasmacytoid dendritic cell neoplasm is a rare hematologic neoplasm characterized by cutaneous, hematologic, and central nervous system (CNS) involvement with poor prognosis. Diagnosis is made by flow cytometry, although there are no specific markers, making its diagnosis challenging. So far, with the available evidence, acute lymphoid leukemia-type schemes and consolidation with allogeneic transplant seem to become the first-line therapy. With its characterization, new therapies directed toward CD 123 and the anti-apoptotic protein Bcl-2 have appeared to prolong the survival of these patients. We present a case of a 27-year-old male patient diagnosed with blastic plasmacytoid dendritic cell neoplasm with unusual CNS manifestations and without skin involvement who achieved complete remission with venetoclax and improvement of neurological symptoms, making him a candidate for hematopoietic stem cell transplant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据